-
Subject Areas on Research
-
A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.
-
A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators.
-
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
-
Ablation of atrial fibrillation during coronary artery bypass grafting: Late outcomes in a Medicare population.
-
Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy.
-
Acute retinal arteriolar emboli after cardiac catheterization.
-
Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry.
-
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
-
An introduction to transoesophageal echocardiography: II. Clinical applications.
-
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
-
Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study.
-
Anticoagulation: choosing the optimal anticoagulant.
-
Anticoagulation: indications and risk classification schemes.
-
Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care.
-
Anticoagulation: monitoring of patients receiving anticoagulation.
-
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
-
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial.
-
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial.
-
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
-
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
-
Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis.
-
Atheroembolic involvement of renal allografts.
-
Atrial septal aneurysm: association with cerebrovascular and peripheral embolic events.
-
Atrial septal aneurysm: recognition and clinical relevance.
-
Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.
-
Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
-
Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.
-
Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies.
-
Central retinal artery occlusion during cardiac catheterization.
-
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban.
-
Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial.
-
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
-
Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
-
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
-
Closed mitral valvotomy for mitral restenosis: experience in 113 consecutive cases.
-
Complications related to percutaneous transvenous mitral commissurotomy.
-
Contemporary outcomes after distal vertebral reconstruction.
-
Coronary embolism and calcified aortic valve: is there a correlation?
-
Current best practices and guidelines. Assessment and management of complications in infective endocarditis.
-
Cutaneous cholesterol embolism of the lower extremities.
-
D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.
-
Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS.
-
Defining risk variables causing gas embolism in loggerhead sea turtles (Caretta caretta) caught in trawls and gillnets.
-
Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway?
-
Early Elevated Troponin Levels After Ischemic Stroke Suggests a Cardioembolic Source.
-
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.
-
Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study.
-
Early predictors of in-hospital death in infective endocarditis.
-
Echocardiographic documentation of vegetative lesions in infective endocarditis: clinical implications.
-
Echocardiography for the detection of cardiac sources of embolism in patients with stroke or transient ischemic attack.
-
Economic impact of new interventional therapies: are we asking the right questions?
-
Edoxaban versus warfarin in patients with atrial fibrillation.
-
Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
-
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
-
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
-
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
-
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
-
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
-
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
-
Embolic central retinal artery occlusion after subcutaneous auricular steroid injection.
-
Embolic protection and platelet inhibition during renal artery stenting.
-
Embolism after inferior vena cava filter mesh fragmentation.
-
Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis.
-
Embolization of patent foramen ovale closure devices: incidence, role of imaging in identification, potential causes, and management.
-
Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): a weighted meta-analysis of 9,251 patients from 46 studies.
-
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
-
Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease.
-
Evaluation of embolization distal to arterial occlusion by transcatheter electrocoagulation (TCEC) and Gianturco coils.
-
Examining biology and pharmacology-based hypotheses in the PLATO trial.
-
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
-
Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
-
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial.
-
Homocysteine and retinal emboli: the Blue Mountains Eye Study.
-
Homocysteine testing in patients with acute ischemic stroke.
-
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
-
Improved microsurgical anastomotic patency with low molecular weight heparin.
-
Increased Left Atrial Appendage Density on Computerized Tomography is Associated with Cardioembolic Stroke.
-
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
-
Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study.
-
Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms.
-
Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial.
-
Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
-
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
-
Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial.
-
Long-Term Embolic Outcomes After Detection of Left Ventricular Thrombus by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Imaging: A Matched Cohort Study.
-
M-mode echocardiographic observations during and after healing of active bacterial endocarditis limited to the mitral valve.
-
M-mode echocardiographic observations in active bacterial endocarditis limited to the aortic valve.
-
Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database.
-
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures.
-
Manual high-dose regional intraoperative thrombolysis of lower extremity emboli after open repair of a ruptured abdominal aortic aneurysm.
-
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
-
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
-
Novel emboli protection cannula during cardiac surgery: first animal study.
-
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
-
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
-
Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
-
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
-
Pathologic quiz case: acute-onset paraplegia in a 60-year-old woman. Spinal cord infarction secondary to fibrocartilaginous (intervertebral disk) embolism.
-
Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.
-
Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation.
-
Percutaneous Thrombectomy in Patients with Occlusions of the Aortoiliac Segment: A Case Series.
-
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
-
Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry.
-
Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry.
-
Prevalence and Associations of Retinal Emboli With Ethnicity, Stroke, and Renal Disease in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Disease Study.
-
Prevalence and risk factors of retinal arteriolar emboli: the Singapore Malay Eye Study.
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
-
Primary intraaortic malignancy--a case report.
-
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
-
Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study.
-
Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid.
-
Reducing the risk of oral contraceptive-induced thrombosis.
-
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
-
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
-
Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
-
Retinal arteriolar emboli and long-term mortality: pooled data analysis from two older populations.
-
Retinal arteriolar emboli: epidemiology and risk of stroke.
-
Right ventricular infarction complicated by acute right-to-left shunting.
-
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.
-
Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
-
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF.
-
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
-
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation.
-
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
-
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.
-
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
-
The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
-
The risk for systemic embolization associated with percutaneous balloon valvuloplasty in adults. A prospective comprehensive evaluation.
-
Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of 8,517 patients.
-
Transesophageal echocardiography before cardioversion.
-
Transesophageal echocardiography in diagnosing cardioembolic stroke.
-
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
-
Uncommon Cause of Fever and Embolism: Staphylococcus epidermidis Infected Myxoma.
-
Urologic surgery.
-
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
-
Value of transthoracic echocardiography in predicting embolic events in active infective endocarditis. Duke Endocarditis Service.
-
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
-
Vegetations in endocarditis: big is bad, but is there more to it?
-
Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility.
-
Keywords of People